Anti-TROP2 Antibody-Drug Conjugate A Targeted Cancer Therapy That Delivers Its Payload to Tumour Cells

This patent covers an antibody-drug conjugate that targets a protein called TROP2, which is found at high levels on many cancer cells. The idea is to use an antibody as a guidance system that carries a cancer-killing drug directly to tumour cells while sparing healthy tissue.

The Problem

Traditional chemotherapy attacks dividing cells throughout the body, which is why it damages healthy tissue and causes severe side effects. A long-standing goal in cancer treatment is to deliver a potent drug only to the cancer cells and leave the rest of the body alone. TROP2 is a cell-surface protein that is overexpressed in many solid tumours, including certain breast, lung and other cancers, which makes it an attractive flag for a targeted therapy. The challenge is building a single medicine that can recognise TROP2, bind tightly to it, and then release a powerful drug payload inside the tumour cell in a controlled way.

What This Invention Does

The patent describes an antibody-drug conjugate in which an anti-TROP2 antibody is chemically joined, through a connecting linker), to a cytotoxic drug payload. The antibody portion seeks out and attaches to TROP2 on the surface of a cancer cell. The conjugate is then taken inside the cell, where the linker releases the drug to kill it from within. By coupling the targeting precision of an antibody with the killing power of a chemotherapy agent, the conjugate is designed to concentrate its effect on TROP2-bearing tumour cells. The patent also covers pharmaceutical compositions containing the conjugate and its use in treating cancer.

Key Features

• TROP2 targeting. An antibody directs the medicine to cells displaying the TROP2 protein.
• Linked drug payload. A cytotoxic drug is attached to the antibody through a chemical linker.
• Intracellular release. The payload is released after the conjugate is taken inside the target cell.
• Reduced off-target effect. Targeting aims to spare healthy cells that do not carry TROP2.
• Therapeutic compositions. The patent includes formulations and methods of treating cancer with the conjugate.

Who Is Behind It

The applicants are Daiichi Sankyo Company, Limited, a major Japanese pharmaceutical company with a strong antibody-drug conjugate research program, and Sapporo Medical University. The named inventors are Toshinori Agatsuma, Shu Takahashi, Jun Hasegawa, Daisuke Okajima, Hirofumi Hamada and Miki Yamaguchi.

Why It Matters

Antibody-drug conjugates are one of the fastest-moving areas of oncology, offering a way to hit tumours hard while reducing the collateral damage of conventional chemotherapy. TROP2 has become an important target because so many solid tumours carry it. Securing protection in Australia for a specific anti-TROP2 conjugate supports the developer’s ability to bring targeted cancer therapies to patients and protects a substantial research investment in this class of medicine.

Related Concepts

• Antibody-drug conjugate – the targeted medicine format at the heart of this patent.
• TROP2 (TACSTD2) – the tumour-cell protein the antibody recognises.
• Monoclonal antibody – the targeting component of the conjugate.
• Targeted therapy – the broader treatment strategy this work belongs to.
• Cytotoxicity – the cell-killing action of the drug payload.

---

AU 2026201915 was published in the Australian Official Journal of Patents on 2 April 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.